Goldman Sachs Group Inc Veracyte, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Veracyte, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,548,474 shares of VCYT stock, worth $44.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,548,474
Previous 1,048,648
47.66%
Holding current value
$44.5 Million
Previous $31.1 Million
34.62%
% of portfolio
0.01%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding VCYT
# of Institutions
297Shares Held
77.5MCall Options Held
0Put Options Held
17.6K-
Vanguard Group Inc Valley Forge, PA8.1MShares$233 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.79MShares$224 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.24MShares$151 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl3.8MShares$109 Million0.85% of portfolio
-
Wellington Management Group LLP Boston, MA3.47MShares$99.9 Million0.02% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.06B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...